Simulations Plus, Inc. (NASDAQ: SLP), the premier provider of simulation and modeling software and consulting services for all phases of pharmaceutical/chemical research and development, announced today that it has extended the Material Transfer Agreement (MTA) with the Division of the National Toxicology Program (DNTP) of the U.S. National Institute of Environmental Health Sciences (NIEHS) for an additional three year term. Simulations Plus will continue to provide licenses for its GastroPlus™, ADMET Predictor™, and MedChem Studio™ software programs for use by the DNTP/NIEHS. The DNTP within the NIEHS is conducting research along with several agencies, including the U.S. Environmental Protection Agency, the U.S. Army, the National Human Genome Institute, and the Centers for Disease Control in the National Toxicology Project.
John DiBella, vice president of marketing and sales for Simulations Plus, said: “We are pleased to continue supporting the research efforts at the DNTP through our modeling & simulation technology. Over the initial two-year term, scientists at the DNTP were impressed with the accuracy of our predictive models and the intuitive way they operated, and they shared their experiences with others by presenting at conferences and webinars. In this next phase of the collaboration, they are interested in exploring the use of physiologically based pharmacokinetic (PBPK) modeling through GastroPlus and to leverage the predictions of concentrations in various tissues to continue prioritizing the many tens of thousands of potentially toxic compounds for testing. Through their feedback, we expect to refine our tools to help with the continued expansion into new markets focused on toxicology research, including industrial chemicals, agrochemicals, and consumer goods companies. To date, our sales efforts have resulted in recent software license orders to several companies and leading research organizations in these sectors.”
About Simulations Plus, Inc.
Simulations Plus, Inc., is a premier developer of groundbreaking drug discovery and development simulation and modeling software which is licensed to and used in the conduct of drug research by major pharmaceutical, biotechnology, agrochemical, and food industry companies worldwide. Simulations Plus also recently acquired Cognigen Corporation of Buffalo, NY, adding to our offerings top quality modeling and simulations using clinical trial data, as well as more than doubling our staff from 30 to 65, adding nearly 50% to revenues, and expecting to increase earnings in the 2015 fiscal year that began September 1. The Company is headquartered in Southern California and trades on the NASDAQ Capital Market under the symbol “SLP.” Cognigen Corp is located in Buffalo, New York. For more information, visit our Web site at www.simulations-plus.com.
Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995 – With the exception of historical information, the matters discussed in this press release are forward-looking statements that involve a number of risks and uncertainties. Words like “believe,” “expect” and “anticipate” mean that these are our best estimates as of this writing, but that there can be no assurances that expected or anticipated results or events will actually take place, so our actual future results could differ significantly from those statements. Factors that could cause or contribute to such differences include, but are not limited to: our ability to maintain our competitive advantages, acceptance of new software and improved versions of our existing software by our customers, the general economics of the pharmaceutical industry, our ability to finance growth, our ability to continue to attract and retain highly qualified technical staff, our ability to identify and close acquisitions on terms favorable to the Company, and a sustainable market. Further information on our risk factors is contained in our quarterly and annual reports as filed with the U.S. Securities and Exchange Commission.